Get a full analysis report for any ticker →

SECTOR COVERAGE

Biotech Stock News

50 STORIES · UPDATED 16H AGO

In biotech the whole thesis often hinges on one FDA decision or trial read-out. We track the catalysts and the cash runway behind them, because a promising pipeline means little if the balance sheet runs dry before approval.

Top StoryABVX

Abivax Falls on Short Seller's Carcinogenicity Allegations

Abivax shares fell 12.4% on November 20 after Scorpion Capital disclosed a short position and published a report alleging undisclosed carcinogenicity risks in obefazimod. Analyst consensus targets $163.58 versus the Friday trading price of $71.74, leaving investors to judge whether the valuation survives the FDA's NDA review.

SMMTAnalysis

Summit Therapeutics' Lung Cancer Drug Rejected by FDA

FDA rejected Summit Therapeutics' ivonescimab BLA for lung cancer because progression-free survival improvements do not establish effectiveness withou…

MANEAnalysis-13%

Veradermics Drops 13% Despite Phase 3 Trial Wins

Veradermics (MANE) dropped 13.3% following positive Phase 3 trial results for VDPHL01, an oral treatment for androgenetic alopecia. However, company i…

ARWRAnalysis-15%

Arrowhead Falls 15% on Pancreatitis Win; Insiders Sold

Arrowhead's plozasiran reduced pancreatitis event rates 78% in Phase 3 trials, but the stock fell 15% on the news, closing at $48.81. Two directors so…

IONSBrief-27%

Ionis Pharmaceuticals Cuts Tryngolza Forecast, Stock Falls 27%

Ionis Pharmaceuticals fell 27% in a single session after cutting its Tryngolza revenue forecast, hitting a 52-week low and raising doubts about whethe…

VIRAnalysis

Vir Biotechnology Insider Sold Days Before 44% HDV Readout

Vir Biotechnology reported 44% Phase 3 response rates in hepatitis delta, with ten patients achieving sustained viral response after 96 weeks off trea…

CGONAnalysis

CG Oncology Beats Q3; Insider Sells For Third Month

CG Oncology beat Q3 earnings estimates with a net loss of $0.64 per share versus the FactSet consensus of $0.84. An insider sold shares in three conse…

RYTMAnalysis

Rhythm's $750M Deal Clouds a Clean Q3 Beat

Rhythm Pharmaceuticals delivered a 17.5% earnings beat in Q3, its fourth consecutive quarter of outperformance, yet shares fell 10% following the anno…

INSMAnalysis

Insmed Q3 Rally Masks $40M Insider Sales at Highs

Insmed rallied on strong Q3 results, but the COO and CMO had already liquidated $40M at prices ($127-$133) the stock now trades well below ($105.07). …

IBRXAnalysis

ImmunityBio Directors Sell $1.1M Before Key Bladder Data

Two ImmunityBio directors sold $1.12M in shares at $10.50–$10.75 in early October, at prices now 32–35% above the stock's current $7.95, weeks before …

ROIVAnalysis

Roivant Officer Files to Sell 7.3M Shares as Citi Lifts PT

Roivant Sciences' president has filed a Form 144 to sell 7.32 million shares, continuing a pattern of insider selling that has totaled $22.31 million …

IOVABrief+10%

Iovance Biotherapeutics Jumps 10% on Fresh Lifileucel Data

Iovance Biotherapeutics surged over 10% after-hours following fresh clinical data on Lifileucel, its lead TIL therapy, testing whether 65.7% revenue g…

SLSBrief-18%

SELLAS Life Sciences Falls 18%: Leukemia Trial Data Due This Quarter

SELLAS Life Sciences dropped 18% after its REGAL Phase 3 leukemia trial hit its pre-specified 80th death event, triggering the final overall survival …

LQDAAnalysis

Liquidia Insiders Sold at $28 Before Patent Settlement

Liquidia's nine C-suite officers sold $25.67M in stock at $28.48 on October 12, two days before the company settled patent litigation with United Ther…

ROIVAnalysis

Roivant Sciences: Phase 3 Win as Insiders Cash Out

Roivant Sciences president Eric Venker sold $14 million in shares over six weeks surrounding two major clinical wins, including $7 million the day bef…

GMABAnalysis

GMAB Ovarian Cancer Drug Cuts Death Risk 57% as Debt Looms

Genmab's ovarian cancer treatment cuts mortality risk 57% versus chemotherapy in late-stage trials, adding to strong pipeline momentum. The stock trad…

CORTAnalysis-20%

Corcept Falls 20% as Rival Cancer Data Overshadows Diabetes Win

Corcept secured ADA endorsement for its diabetes treatment, but Genmab's Phase 3 ovarian cancer data proved superior in the identical indication where…

SLSAnalysis

SELLAS CEO Claims GPS Has 'Very Good Chance' to Beat AML

CEO Angelos Stergiou has stated GPS has a "very good chance" to beat prior survival outcomes, with SELLAS's $2.42 billion valuation staked almost enti…

SLSAnalysis

SELLAS AML Readout Two Events Away as Retail Bets Surge

SELLAS Life Sciences is two death events away from final analysis on its Phase 3 AML trial, the sole catalyst for the stock. While retail investors bi…

IOVAAnalysis

Iovance Trades Premium Despite 13-Month Cash Runway

Iovance Biotherapeutics trades above the $14.40 analyst consensus price target following September guidance raise, but the company holds only 13 month…

PLSEAnalysis

Pulse Bio AF Trial Enrolls Early But Runway Tightens

Pulse Biosciences enrolled 164 evaluable patients in its atrial fibrillation pivotal trial three months ahead of schedule, moving the nPulse Cardiac C…

PRAXAnalysis

Praxis Jumps on FDA Bets as UBS Targets $706, 171% Upside

Praxis Precision Medicines has a $7.26 billion market cap despite zero revenue, supported by two pending FDA verdicts for ulixacaltamide and relutrigi…

IOVAAnalysis

Iovance Debuts Sarcoma Data as Cash Runs Low

Iovance presented the first TIL cell therapy data in soft tissue sarcomas at ESMO, expanding the platform beyond melanoma. The company's $300 million …

SMMTAnalysis

Summit Therapeutics Trades Below AstraZeneca's $18.36

AstraZeneca's $2 billion investment in Summit Therapeutics at $18.36 per share is now worth less on paper, with the stock trading at $14.63 as 26.3% s…

RDYAnalysis

Dr. Reddy's 200-Day Breakout Faces FDA Visakhapatnam Risk

Dr. Reddy's Laboratories crossed above its 200-day moving average this week, a technical milestone that coincided with FDA pre-approval inspection obs…

ARWRAnalysis

Arrowhead Insiders Sold at $87; UBS Now Targets $109

Arrowhead Pharmaceuticals' interim Alzheimer's data showed 73% mean CSF tau reduction at Day 105, prompting UBS to raise its price target to $109 on O…

RDYAnalysis

Dr. Reddy's Faces FDA Flags Ahead of Friday Earnings

Dr. Reddy's received FDA pre-approval inspection observations at two manufacturing sites just days after rallying past its 200-day moving average. Wit…

TGTXAnalysis

TGTX Soars on Buyout Rumors, but Director Sold Weeks Prior

TG Therapeutics (TGTX) stock surged to a 3.5-month high on acquisition rumors. However, a director sold shares five weeks earlier and no SEC filing co…

HALOBrief

Halozyme Therapeutics Patent Win Lifts Analyst Targets on $116 Stock

A patent victory protecting Halozyme's ENHANZE subcutaneous delivery platform reduces genericization risk for its high-margin royalty stream, driving …

PBLSAnalysis

Parabilis Shares Slip Below Ra Capital's Buy Zone

Ra Capital accumulated Parabilis shares at $27-$30 per share in July, but the company's 772% EPS miss has left the cost basis underwater. The stock tr…

IDYAAnalysis

IDEAYA CEO Cashes Out $985K at 46% Discount to Consensus

IDEAYA's CEO sold $985K in stock at a 46% discount to analyst consensus price targets on October 6, just eight days after the company promoted its R&D…

IBRXBrief+11%

ImmunityBio Surges 11% as ANKTIVA Sales Drive 94% Revenue Growth

ImmunityBio's Q4 showed 94% YoY revenue growth driven by ANKTIVA commercial sales, lifting the stock 11%, but the company burns more cash than it earn…

IONSAnalysis

Ionis CSO Sells $1.7M as Stock Falls to $44 vs $84 Target

Three Ionis executives, including the Chief Scientific Officer, sold $2.6 million in shares at $83-$85 in July. The stock has since fallen 46% to $44.…

SMMTBrief

AstraZeneca Backs Summit Therapeutics With $2 Billion Investment

AstraZeneca invested $2 billion in Summit Therapeutics while strong ivonescimab lung cancer survival data hit simultaneously, removing the capital-fai…

TWSTAnalysis

Twist CEO Sells $56M at Rally Peak, Stock Tops Targets

Twist Bioscience CEO Emily Leproust sold $56.33M on September 17 at the peak of a 33% rally tied to the Lilly TuneLab partnership, cashing out deeply …

SMMTAnalysis

Summit Therapeutics Phase III Beats Keytruda, Burns $458M

Summit Therapeutics' ivonescimab achieved Phase III superiority over pembrolizumab in non-small cell lung cancer, posting 30.8 months median overall s…

PRAXAnalysis-12%

PRAX Falls 12% After Trial Setback Following Analyst Boost

Praxis Precision Medicines dropped 12% after-hours following a trial setback, just three days after analysts issued upgrades projecting 91% upside. Wi…

NAMSAnalysis

NAMS CSO Sold $3.4M Before Phase 3 Data Readout

NewAmsterdam Pharma's Chief Scientific Officer sold $3.4M worth of shares on August 24, immediately before the company's Phase 3 Obicetrapib data read…

PLSEAnalysis

Pulse Bio COO Buys Above Analyst Target at All-Time High

Pulse Biosciences COO bought nearly $200K of stock above analyst targets as shares hit all-time highs, signaling conviction in the company's cardiac c…

PBLSAnalysis

Parabilis Medicines: Why Ra Capital Keeps Buying $5B Bet

Parabilis Medicines, valued at $5 billion with zero revenue, posted a -772.6% EPS miss in its first public quarter. Yet Ra Capital, which anchored the…

PBLSAnalysis

Parabilis Q2 EPS Miss Doesn't Deter Ra Capital Buying

Parabilis Medicines reported a Q2 EPS of -$2.12, missing consensus by 772.6% on zero trailing revenue. Despite this, Ra Capital—which invested $394 mi…

MBXAnalysis-7.5%

MBX Biosciences Stock Falls 7.5% on Phase 3 Trial Launch

MBX stock fell 7.5% on the Phase 3 trial launch announcement, but the market was actually reacting to the Q2 earnings miss that signaled potential los…

MANEAnalysis

Veradermics Insiders Sold $103M as Stock Peaked

Veradermics insiders including the CEO, CTO, and a board director collectively sold $103.12 million in stock at $106 to $111 per share in the two week…

ARWRAnalysis

Arrowhead's 750-Patient Heart Data: A $12B Test

Arrowhead Pharmaceuticals carries a $12 billion market cap sustained entirely by episodic milestone payments from GSK, Takeda, Amgen, and Sarepta, wit…

ALMSAnalysis

Alumis: Six Officers Sold at $26.37 on a 10% Down Day

Six Alumis executives sold 14,953 shares at $26.37 on August 3, a session where the stock fell 10%, generating roughly $394,000 in combined proceeds p…

NAMSAnalysis

NewAmsterdam Pharma: CAO Sold $6.7M, Stock Below Floor.

NewAmsterdam Pharma's CAO sold $6.71 million in shares across three months at prices between $29.96 and $35.69, and the stock now trades at $27.79, be…

TRVIAnalysis

Trevi Therapeutics: Fidelity Buys 8.8% After Q2 Miss

Trevi Therapeutics posted a second consecutive EPS miss in Q2 2026 while FMR LLC disclosed an 8.8% ownership stake, with institutional investors colle…

IONSAnalysis

Ionis Insiders Sold at $85, Then Bought at $52

Goldman Sachs raised its Ionis Pharmaceuticals price target today, lifting shares 4% in after-hours trading, yet the stock sits roughly 28% below the …

AMLXAnalysis

Amylyx Files Offering Same Day as Phase 3 Win

Amylyx Pharmaceuticals surged 45% after Avexitide posted positive Phase 3 results for post-bariatric hypoglycemia and congenital hyperinsulinism, cond…

AMLXBrief+45%

Amylyx Pharmaceuticals Jumps 45% as Trial Cuts Hypoglycemia by 55%

Amylyx Pharmaceuticals surged 45% in a single trading session after its experimental drug showed a 55% reduction in dangerous hypoglycemia events, a c…

Keep going

Your move

Run this same teardown on a stock you actually own.

Drop in any ticker and get an institutional-grade report in about 60 seconds — the full DCF, an earnings-quality score, and the red flags buried deep in the filing. No signup, no card.

Run a free report →
  • DCF valuation with bull & bear cases
  • Earnings-quality score from 0–100
  • Red-flag scan across the 10-K
  • Peer multiples & a fair-value range